investing.comOct 19$ZNTL

H.C. Wainwright reiterates Zentalis stock rating on survival data

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Zentalis Pharmaceuticals (ZNTL) after positive survival data from its DENALI Part 1b trial. The stock has fallen 15% in a week, trading at $2.13. The trial showed cyclin E1-positive patients had a median overall survival of 15.8 months. The company has strong cash reserves and a high current ratio, supporting ongoing trials. Other analysts also initiated coverage with positive ratings and price targets.

Original reporting

investing.com

Published Oct 19, 2026, 12:56 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 19, 2026, 1:08 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefTechnology

Primary signal

$ZNTL

Bullish

high confidence

Mentioned

$ZNTL

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$ZNTLBullishHigh

Why it matters

The interim survival data provides a catalyst that could shift the stock toward the $10 target, influencing short‑term trading decisions.

Market read

New trial data and analyst coverage together create a fresh catalyst for Zentalis, likely prompting price movement.

What to watch

Potential competition from other cyclin‑targeting agents and the need for regulatory approval timelines.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is a clinical‑stage biotech developing a WEE1 inhibitor for cyclin E1‑positive ovarian cancer.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ZNTLBullishHigh confidence

Context

H.C. Wainwright reiterated a Buy rating and $10 price target after Zentalis reported interim overall survival data from the DENALI Part 1b trial.

Expected impact

likely upside as market prices in the favorable survival results

Evidence & confidence

The trial showed a median overall survival of 15.8 months in cyclin E1‑positive patients, a material improvement that can drive the stock toward the new $10 target.

Market effects

Sector

strengthens the oncology biotech sector by demonstrating progress on a first‑in‑class WEE1 inhibitor.

Regional

U.S. biotech investors may increase exposure to early‑stage cancer therapeutics.

Global

Positive data could attract international investors seeking high‑growth biotech opportunities.

Counterpoint

What could challenge this read

If the upcoming Phase 3 data fails to confirm efficacy, the current upside may be overstated.

Key entities

analyst
H.C. Wainwright
Equity research firm reiterating a Buy rating on Zentalis.
clinical_trial
DENALI Part 1b trial
Interim overall survival study of azenosertib in cyclin E1‑positive patients.

Read at source ← All news

$ZNTLMed

Wedbush upgrades Zentalis Pharmaceuticals to Outperform from Neutral, raises price target to $6 from $5

Wedbush upgraded Zentalis Pharmaceuticals to Outperform from Neutral, raising its price target to $6 from $5, a 20% increase. The target implies a 244.8% upside from the Nov 9 close of $1.74.

tradingview.comNov 10

$ZNTLHigh

Why is Zentalis Pharmaceuticals stock climbing today?

Zentalis Pharmaceuticals (ZNTL) stock rose 5.2% in pre-market trading after beating Q3 2026 earnings estimates with a loss of $0.34 per share, better than the $0.58 estimate. The company reported $228.89 million in cash and expects to complete a clinical trial by November 2026, with a readout in early 2027. Analysts maintain a 'Buy' rating with a $7.33 price target.

investing.comNov 10

$ZNTLMed

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates • DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-po

SEC EDGAR 8-KNov 9

$ZNTLMedAI 9/10

Zentalis reports survival data for ovarian cancer drug trial

Zentalis Pharmaceuticals (ZNTL) reported interim results from its DENALI Part 1b study of azenosertib for ovarian cancer at the ESMO Congress. The trial showed median overall survival of 15.9 months in Cyclin E1-positive patients and 7.5 months in negative patients. The study enrolled 102 heavily pretreated patients, with a 33.3% objective response rate in evaluable Cyclin E1-positive patients. Common adverse events included nausea and fatigue.

investing.comOct 23

$ZNTLHighAI 8/10

Zentalis Pharmaceuticals, Inc. (ZNTL) Posts Interim OS Benefit in Cyclin E1+ PROC

Zentalis Pharmaceuticals reported interim data from DENALI Part 1b, showing median overall survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) patients, compared to 7.5 months in Cyclin E1-negative patients. The safety profile was consistent with prior reports, and the study supports azenosertib as a potential treatment. DENALI Part 2 and ASPENOVA Phase 3 trials are ongoing.

tradingview.comOct 23